Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An adaptive, pivotal phase II/III trial of SM-88 in combination with gemcitabine (Gemzar®) and nab-paclitaxel (Abraxane®) in patients with pancreatic cancer

Trial Profile

An adaptive, pivotal phase II/III trial of SM-88 in combination with gemcitabine (Gemzar®) and nab-paclitaxel (Abraxane®) in patients with pancreatic cancer

Planning
Phase of Trial: Phase II/III

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs SM 88 (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Precision Promise
  • Sponsors Tyme Technologies
  • Most Recent Events

    • 11 Feb 2019 According to a Tyme Technologies media release, this trial is expected to begin in first half of 2019.
    • 05 Nov 2018 According to a Tyme Technologies media release, the company expects to start two potentially registrational arms with: 1) monotherapy SM-88 in second-line patients, and 2) SM-88 in combination with gemcitabine/Abraxane in both first- and second-line patients during calender year 2019.
    • 17 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top